Navigation Links
US HIFU Secures $5 Million Financing From MMV Financial
Date:7/29/2009

CHARLOTTE, N.C., July 29 /PRNewswire/ -- US HIFU, LLC, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound technologies, has secured a $5 million financing commitment from Toronto-based MMV Financial ("MMV").

US HIFU continues to pioneer on-going cutting-edge clinical research, including immunotherapy and focal therapy, for the treatment of prostate cancer. The company looks forward to expanding plans for clinical trials that will give patients the option to pursue focal therapy, where only the cancerous part of the prostate is removed instead of the whole gland. Studies outside the U.S. have shown that focal therapy may reduce side effects and offer effective cancer control.

"We believe that HIFU is the best positioned energy source to deliver focal therapy. There is a growing trend toward less invasive treatments and a paradigm shift in how prostate cancer is being managed internationally. Currently patients must choose between either active surveillance or radical intervention which are at opposite ends of the spectrum. Focal therapy may represent an optimal hybrid between the extremes that can be viewed as therapeutic surveillance, an approach that seeks to find a balance between cancer control and quality of life considerations. We have secured financing in order to speed the maturation of focal therapy; and we look forward to announcing the start of clinical trials evaluating focal therapy to be conducted at some of the nation's top academic centers in the coming weeks," said Steve Puckett, Jr., Chief Executive Officer, US HIFU. "It is an exciting time for HIFU as a technology and this financing allows us to dedicate even more resources to expanding our clinical trials research program which is dedicated to improving the treatment of patients with prostate cancer."

"MMV is proud to be part of the continuing development of this breakthrough technology and its promise of new hope for thousands of prostate cancer patients," said April Young, Senior Vice President and Managing Director, US, MMV Financial.

About US HIFU, LLC

US HIFU, LLC is a privately held healthcare company focused on treating primary and recurrent prostate cancer using HIFU, a minimally invasive outpatient procedure. US HIFU was founded in 2004 and is headquartered in Charlotte, N.C.

About the Sonablate((R)) 500

The Sonablate((R)) 500 is a minimally invasive medical device that utilizes ultrasound energy to destroy tissue within the body. It was developed by Focus Surgery, Inc. and is manufactured by Misonix, Inc. (NASDAQ: MSON) who also holds distribution rights in Europe. Takai Hospital Supply Ltd. and THS International distribute the Sonablate((R)) 500 in Southeast Asia and the Middle East. The Sonablate((R)) 500 is not approved for use in the U.S. The Sonablate((R)) 500 remains investigational in the U.S. and is being studied for the treatment of prostate cancer in clinical trials in the U.S. FDA has made no decision as to the safety or efficacy of the Sonablate((R)) 500 for the treatment of prostate cancer.

About MMV Financial

MMV Financial is a Toronto-based specialty finance company providing creative debt solutions directly to technology and life sciences companies across North America. MMV is backed by top U.S. and Canadian private equity firms and financial institutions including CCP Equity Partners, Caisse de depot et placement du Quebec, Fonds de Solidarite des Travailleurs du Quebec, HSBC Bank Canada, NewStar Financial Inc., ROI Capital, and Wells Fargo Company. For more information please visit: www.mmvf.com.


'/>"/>
SOURCE US HIFU
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
2. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
3. UI licensee Optherion secures $37 million in financing
4. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
5. Piedmont Pharmaceuticals Secures $8.5 Million Investment
6. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
7. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
8. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
9. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
10. InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group
11. Asoyia Secures Venture Capital Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... , , , WHEN: ... , , , , LOCATION: , , , Online, with ... , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global Vice ... Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... industry is witnessing an exceptional era. Several new demand spaces, such ...
(Date:6/23/2016)... Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new ... affiliate in Latin America . ... ... ... ...
Breaking Medicine Technology: